The team of LeucoTox has discovered an unprecedented mechanism for the treatment of acute myeloid leukemia (AML). This immuno-oncological mechanism is based on two distinct yet highly complementary mechanisms:

(i) the activation of signaling pathways of non-apoptotic programmed cell death that compromise cellular integrity specifically in leukemic cells while healthy hematopoietic stem and progenitor cells remain largely unaffected.

(ii) induction of a mild inflammatory reaction within the bone marrow stroma resulting in the proliferation of healthy stem and progenitor cells and a competition for niche space between malignant and healthy bone marrow cells (functional competition plus spatial competition).